Lv1
76 积分 2024-03-08 加入
Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer
1个月前
已完结
α-Synuclein pathology as a target in neurodegenerative diseases
2个月前
已完结
Therapeutic targeting of the KIF18A motor protein in cancers with chromosomal instability
4个月前
已完结
The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: is it really that simple?
5个月前
已完结
Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer
5个月前
已完结
Prostate Cancer
5个月前
已完结
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2
6个月前
已完结
Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRI‐characterized prostates
7个月前
已完结
Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer
7个月前
已完结
Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer
7个月前
已完结
皖公网安备34019202002308
